Gibson Christopher 4

What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), converted 40,000 convertible Class B shares into Class A common stock and sold 40,000 Class A shares in an open-market transaction on April 22, 2026. The shares sold were transacted at $3.61 per share for total proceeds of $144,400. The conversion was recorded at $0.00 per share (no cash payment for conversion).

Key Details

• Transaction date: April 22, 2026. Sale price: $3.61 / share; total proceeds $144,400.
• Conversion: 40,000 Class B shares converted to Class A (recorded at $0.00).
• Sale type: Open market sale reported under Form 4. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025 (footnote F2).
• Shares owned after transaction: Not specified in the provided filing data.
• Relevant footnotes: F1 (Class B shares are convertible into Class A at holder's option, no expiration) and F2 (10b5-1 plan). Other vesting/holding footnotes in the filing relate to separate option and entity holdings.

Context
This was a conversion of convertible shares followed by an immediate open-market sale — not an option exercise-for-stock-and-hold. The use of a pre-established 10b5-1 plan indicates the sale was prearranged; such planned sales are commonly used to avoid appearance of trading on material nonpublic information. The filing appears timely (filed April 24, 2026, for the April 22 transaction).